• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring and Mutations.携带 和 突变的去势抵抗性前列腺癌患者中，循环肿瘤 DNA 假阳性结果不能解释 PARP 抑制剂疗效缺乏的原因。
JCO Precis Oncol. 2024 Aug;8:e2400354. doi: 10.1200/PO.24.00354.
2
Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis.聚（ADP - 核糖）聚合酶（PARP）抑制剂在转移性去势抵抗性前列腺癌治疗效果中的异质性：一项实时交互式系统评价与荟萃分析
Eur Urol. 2025 Jan 22. doi: 10.1016/j.eururo.2024.12.007.
3
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.同源重组修复基因突变转移性去势抵抗性前列腺癌中个体基因的多聚（ADP-核糖）聚合酶抑制剂的疗效：美国食品和药物管理局的汇总分析。
J Clin Oncol. 2024 May 10;42(14):1687-1698. doi: 10.1200/JCO.23.02105. Epub 2024 Mar 14.
4
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.同时存在 BRCA2/SPOP 突变可预测转移性去势抵抗性前列腺癌对聚（ADP-核糖）聚合酶抑制剂的敏感性。
Eur Urol Oncol. 2024 Aug;7(4):877-887. doi: 10.1016/j.euo.2023.11.014. Epub 2023 Dec 9.
5
The Impact of Uncommon HRR Alterations as Predictors of Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.罕见的同源重组修复改变作为PARP抑制剂治疗转移性去势抵抗性前列腺癌疗效预测指标的影响：一项随机对照试验的荟萃分析
Target Oncol. 2025 Apr 17. doi: 10.1007/s11523-025-01141-9.
6
Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis.多聚（ADP-核糖）聚合酶抑制剂在 BRCA 阳性转移性去势抵抗性前列腺癌患者中与铂类化疗具有相当的疗效。系统评价和荟萃分析。
Eur Urol Oncol. 2024 Jun;7(3):365-375. doi: 10.1016/j.euo.2023.09.001. Epub 2023 Sep 16.
7
Impact of homologous recombination repair/BReast CAncer (BRCA) gene alterations on survival in a real-world setting of metastatic prostate cancer.同源重组修复/乳腺癌（BRCA）基因改变对转移性前列腺癌真实世界生存情况的影响。
BJU Int. 2025 Jan;135(1):117-124. doi: 10.1111/bju.16462. Epub 2024 Jul 10.
8
Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer.尼拉帕利联合醋酸阿比特龙与其他一线多聚（ADP-核糖）聚合酶抑制剂治疗方案治疗 BRCA1/2 突变阳性转移性去势抵抗性前列腺癌患者的间接治疗比较的可行性。
Adv Ther. 2024 Aug;41(8):3039-3058. doi: 10.1007/s12325-024-02918-6. Epub 2024 Jul 3.
9
Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic.循环肿瘤 DNA 检测在前列腺癌同源重组修复基因中的应用：从实验室到临床。
Int J Mol Sci. 2021 May 24;22(11):5522. doi: 10.3390/ijms22115522.
10
The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis.PARP 抑制剂在 HRR 突变的 mCRPC 二线治疗中的疗效和安全性：系统评价和贝叶斯网络荟萃分析。
BMC Cancer. 2024 Jun 8;24(1):706. doi: 10.1186/s12885-024-12388-2.

本文引用的文献

1
Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer.朝着在前列腺癌中明智选择和解释临床基因组测试的方向发展。
JCO Precis Oncol. 2024 Mar;8:e2300654. doi: 10.1200/PO.23.00654.
2
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.同源重组修复基因突变转移性去势抵抗性前列腺癌中个体基因的多聚（ADP-核糖）聚合酶抑制剂的疗效：美国食品和药物管理局的汇总分析。
J Clin Oncol. 2024 May 10;42(14):1687-1698. doi: 10.1200/JCO.23.02105. Epub 2024 Mar 14.
3
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.阿比特龙联合奥拉帕利治疗转移性去势抵抗性前列腺癌
NEJM Evid. 2022 Sep;1(9):EVIDoa2200043. doi: 10.1056/EVIDoa2200043. Epub 2022 Jun 3.
4
Impact of DNA damage repair alterations on prostate cancer progression and metastasis.DNA损伤修复改变对前列腺癌进展和转移的影响。
Front Oncol. 2023 Jun 26;13:1162644. doi: 10.3389/fonc.2023.1162644. eCollection 2023.
5
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.泰拉唑帕尼联合恩扎卢胺治疗一线转移性去势抵抗性前列腺癌（TALAPRO-2）：一项随机、安慰剂对照、III 期临床试验。
Lancet. 2023 Jul 22;402(10398):291-303. doi: 10.1016/S0140-6736(23)01055-3. Epub 2023 Jun 4.
6
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.尼拉帕利与醋酸阿比特龙治疗转移性去势抵抗性前列腺癌。
J Clin Oncol. 2023 Jun 20;41(18):3339-3351. doi: 10.1200/JCO.22.01649. Epub 2023 Mar 23.
7
Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.对 3334 例晚期前列腺癌患者循环肿瘤 DNA 的基因组分析鉴定出可靶向的 BRCA 改变和 AR 耐药机制。
Clin Cancer Res. 2021 Jun 1;27(11):3094-3105. doi: 10.1158/1078-0432.CCR-20-4805. Epub 2021 Feb 8.
8
Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference.DNA 修复基因中克隆性造血与前列腺癌无细胞血浆 DNA 检测干扰的关联。
JAMA Oncol. 2021 Jan 1;7(1):107-110. doi: 10.1001/jamaoncol.2020.5161.
9
A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer.前列腺癌中 DNA 损伤反应基因突变的流行情况系统评价。
Int J Oncol. 2019 Sep;55(3):597-616. doi: 10.3892/ijo.2019.4842. Epub 2019 Jul 16.
10
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.意义未明的克隆性造血及其与骨髓增生异常综合征的鉴别
Blood. 2015 Jul 2;126(1):9-16. doi: 10.1182/blood-2015-03-631747. Epub 2015 Apr 30.

携带 和 突变的去势抵抗性前列腺癌患者中，循环肿瘤 DNA 假阳性结果不能解释 PARP 抑制剂疗效缺乏的原因。

False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring and Mutations.

机构信息

Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, MD.

Oncology Center of Excellence (OCE), U.S. Food and Drug Administration, Silver Spring, MD.

出版信息

JCO Precis Oncol. 2024 Aug;8:e2400354. doi: 10.1200/PO.24.00354.

DOI:10.1200/PO.24.00354
PMID:39208375
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11371381/
Abstract

False-positive ctDNA results do not explain lack of efficacy for PARPi in patients with ATMm and CHEK2m CRPC.

摘要

假阳性 ctDNA 结果并不能解释 ATMm 和 CHEK2m CRPC 患者中 PARPi 无效的原因。